

Alaska Medicaid Pharmacy and Therapeutics Committee

Meeting date February 13, 2004

Frontier Building, 3601 C Street; Room 880/890

Agenda

Call in: 1-800-315-6338. Use access code 735#.

Drug classes to be discussed as time allows.

Call to order - Chair

Richard Brodsky, MD 8:00 a.m.

Roll call

8:00 – 8:10

Public Comment - (See guidelines on page 2)

8:10 to 8:55

P&T Questions & Comments for public

Herpetic Antivirals - Antiviral for herpes viral infection

Sandy Kapur, Pharm D Time as needed

- Time for Herpetic Antivirals - discussion & vote
- Vote on motions

BREAK

Approx 10:00 a.m.

Macrolides - Antibiotic

Sandy Kapur, Pharm D Time as needed

- Time for discussion on Macrolides - Antibiotic
- Vote on motions

Second Generation Cephalosporins - Antibiotic

Sandy Kapur, Pharm D Time as needed

Third Generation Cephalosporins - Antibiotic

- Time for discussion and vote on Second and Third Generation Cephalosporins
- Vote on motions

Onychomycosis Antifungals - Antifungal

Sandy Kapur, Pharm D Time as needed

- Time for discussion & vote on Onychomycosis
- Vote on motions

Short Acting Beta-Adrenergics (MDI and Nebs);

Sandy Kapur, Pharm D Time as needed

Long Acting Beta Adrenergics - Inhaled anti-asthmatic drugs

- Time for discussion & vote on Short Acting and Long Acting Beta-Adrenergics
- Vote on motions

Classes for next P&T meeting

5 minutes

Final Comments by Chair or other members

5 minutes

Closing

Noon or before

GUIDELINES FOR PROVIDING COMMENT to the ALASKA P&T COMMITTEE
February 13, 2004

1. All interested speakers will be required to provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area.
2. The time on the agenda for each agenda item is limited. An individual's comments to the committee are limited to a maximum of five (5) minutes in total.
3. Only one speaker "slot" will be available per meeting representing a single manufacturer or interest group. Within the allowable five (5) minute time period, multiple speakers may share this "slot".
4. NO reference or information as to pricing is allowed in any comment(s). Such information will be considered reason for immediately ending the comment opportunity.
5. It is requested that comment provided in relation to specific medications be directed toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results or synergistic outcomes which have been demonstrated.
6. Written medical information is not accepted at the P&T meeting. This is to be submitted First Health prior to the meeting.